Ribon Therapeutics doses first patient in RBN-2397 Phase 1 trial
Category: #health  By Pankaj Singh  Date: 2019-09-06
  • share
  • Twitter
  • Facebook
  • LinkedIn

Ribon Therapeutics doses first patient in RBN-2397 Phase 1 trial
  • The Phase 1 clinical trial assessing RBN-2397 will be the first clinical evaluation of monoPARP Inhibitor.
     
  • RBN-2397 is the company’s PARP7 inhibitor and is capable of potently inhibiting cancer cell proliferation.

Ribon Therapeutics, a biotech company involved in the development of cutting-edge therapeutics that targets novel enzyme families that are activated by cellular stress conditions, recently announced that it dosed the first patient in a Phase 1 clinical trial that assesses RBN-2397, which is its first-in-class PARP7 inhibitor.

Apparently, PARP7 belongs to an enzyme family that gets activated by cellular stress conditions, called the monoPARPs, that are different from polyPARPs like PARP1/2. New research pioneer by Ribon has exhibited that monoPARPs as the main regulators of responses to stress and have been linked to the formation of diseases like cancer.

Chief Medical Officer at Ribon Therapeutics, Sudha Parasuraman, M.D., said that the company is aiming to target PARP7 with the help of RBN-2397, PARP7 plays an important role in the survival of cancer cells. Inhibiting PARP7 has the ability to potently inhibit the proliferation of cancer cells as well as release a ‘brake’ which the cancer cells utilize to evade the immune system.

Parasuraman further continued that the company has seen a strong preclinical evidence that supports RBN-2397’s clinical potential and also believes that the inhibitor could prove to be a valuable treatment option for patients suffering from cancer.  

Chief Executive Officer and President at Ribon Therapeutics, Victoria Richon, Ph.D., said that bringing in the company’s lead compound in the clinic is a major milestone for Ribon and it demonstrates the company’s ability to advance the program initiation into a clinic within three years. The progress shown by Ribon validates the efficiency and utility of the company’s platform which has rapidly been involved in the development of clinical drug candidates and interrogation of novel biological pathways.

Richon further added, the platform has a wide potential application that enables the company to develop top-of-the-line therapeutics to fight an increasing set of targets in neurodegeneration, inflammatory disease and oncology.

 

Source Credit- https://ribontx.com/ribon-therapeutics-announces-dosing-of-first-patient-in-phase-1-clinical-trial-of-rbn-2397-a-first-in-class-parp7-inhibitor/



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Amazon to open new fulfillment center with 500 jobs in Coweta County
Amazon to open new fulfillment center with 500 jobs in Coweta County
By Pankaj Singh

Brian Kemp, the 83rd Governor of Georgia, has recently announced that Amazon will be launching a new fulfillment center in Newman, adding 500 full-time jobs at the new facility in Coweta County. Employees in...

Payless emerges from Chapter 11 bankruptcy to reopen U.S. stores
Payless emerges from Chapter 11 bankruptcy to reopen U.S. stores
By Pankaj Singh

Payless ShoeSource has emerged from Chapter 11 bankruptcy for the second time and is planning a comeback after the closure of Brookville distribution center and retail stores in 2019. The company is currently focusing ...

Amazon puts an end to FedEx Ground ban for third-party Prime shipments
Amazon puts an end to FedEx Ground ban for third-party Prime shipments
By Pankaj Singh

Amazon, a leading company in the e-Commerce sector, has recently decided to lift its shipping ban on FedEx Ground deliveries for third-party Prime deliveries. Under the new agreement, third-party sellers will have acce...